External Quality Assessment Scheme

#### Lipids and Lipoproteins Lp(a) Round 1, 2023

#### **Specimens**

Please find enclosed 2 liquid human serum samples S001 and S002, each 0.5 mL. Sample S003 is a lyophilized product obtained from human serum, à 1 mL.

#### Caution

Quality control specimens derived from human blood must be handled with the same care as patient samples, i.e. as potential transmitters of serious diseases. The specimens are found to be HBsAg, HCVAb and HIVAgAb negative when tested with licensed reagents, but no known test method can offer complete assurance that the specimens will not transmit these or other infectious diseases.

#### **Examinations**

Please see page 3.

#### Storage and use

Samples S001 and S002 are ready for use and they should be analysed as soon as possible after arrival, within a week. Store the samples in a refrigerator, do not freeze. The specimens should be analysed as usual patient samples.

#### Note! Sample S003 is only for analyze of Lp(a).

Reconstitution of Sample S003: Open the vial carefully and reconstitute the contents <u>in 1 mL</u> of distilled water by carefully rotating the vial. Allow the reconstituted serum to stand for 30 min at room temperature before use. Stability after reconstitution is 14 days in  $2...8\,^{\circ}$ C.

#### Result reporting

Please enter the results and methods via LabScala. If you can't find your instrument or reagent from the registry, please contact the EQA Coordinator.

S001:



S002:



S003:



#### 2023-02-21

#### **INSTRUCTIONS**

Product no. 2200, 2202 LQ735323011-013/FI, UK

Subcontracting: Sample preparation, Sample pretesting

If the kit is incomplete or contains damaged specimens, please report immediately to info@labquality.fi.

The results should be reported no later than **March 16, 2023**.

#### Inquiries

EQA Coordinator Satu Eklund satu.eklund@labquality.fi

#### Labquality

Kumpulantie 15 FI-00520 HELSINKI Finland

Tel. + 358 9 8566 8200 Fax + 358 9 8566 8280

info@labquality.fi www.labquality.com





Lipids and lipoproteins Lp(a)


#### Examinations


Cholesterol HDL cholesterol LDL cholesterol lipoprotein apo A1 lipoprotein apo A2 lipoprotein apo B triglycerides

lipoprotein (a)




#### S-Chol |Integra400+





	x <sub>pt</sub>	sd	SEM	CV%	n
Photometry, enzymatic, Roche Chol	4.85 mmol/l	0.08	0.02	1.6	14
All methods	4.90 mmol/l	0.14	0.02	2.8	37

	<sup>X</sup> pt	sd	SEM	CV%	n
Photometry, enzymatic, Roche Chol	2.66 mmol/l	0.06	0.01	2.1	14
All methods	2.70 mmol/l	0.09	0.02	3.4	37




Round	Sample	<sup>X</sup> pt	Result	diff%	z-score
23/1	Sample S002	2.66	2.66	-0.14%	-0.07
23/1	Sample S001	4.85	4.81	-0.79%	-0.51






#### S-Chol-HDL |Integra400+

LABQUALITY





Histo	ory						
	-10%	diff% 0%	10%				
23/1   Sample S002		▼▲					
23/1   Sample S001	•	<b>A</b>					
	-2	0 z-score	2				
diff% ▼ z-score							


	<sup>X</sup> pt	sd	SEM	CV%	n
Direct measurement, HDL-chol, Roche-systems	1.67 mmol/l	0.04	0.01	2.4	14
All methods	1.64 mmol/l	0.07	0.01	4.1	37

	<sup>X</sup> pt	sd	SEM	CV%	n
Direct measurement, HDL-chol, Roche-systems	1.27 mmol/l	0.03	<0.01	2.3	14
All methods	1.26 mmol/l	0.06	0.01	5.0	37

Round	Sample	<sup>X</sup> pt	Result	diff%	z-score
23/1	Sample S002	1.27	1.25	-1.70%	-0.73
23/1	Sample S001	1.67	1.62	-2.70%	-1.11



#### S-Chol-LDL |Integra400+



<sup>X</sup>pt

2.73

2.85

mmol/l

mmol/l

Direct measurement,

LDL-chol,

Roche-systems

All methods


SEM CV% n

15


37

0.06 0.02 2.4

0.18 0.03 6.3



	<sup>X</sup> pt	sd	SEM	CV%	n
Direct measurement, LDL-chol, Roche-systems	0.68 mmol/l	0.02	<0.01	2.9	15
All methods	0.79 mmol/l	0.19	0.03	23.4	37




Round	Sample	x <sub>pt</sub>	Result	diff%	z-score
23/1	Sample S002	0.68	0.69	1.86%	0.65
23/1	Sample S001	2.73	2.73	0.03%	0.01





#### S-Trigly |Integra400+



<sup>X</sup>pt

1.05

1.03

mmol/l

mmol/l

Photometry, enzymatic, Roche

trigĺy

All methods


SEM CV% n

14


37

0.03 < 0.01 3.0

0.05 < 0.01 5.2



	<sup>X</sup> pt	sd	SEM	CV%	n
Photometry, enzymatic, Roche trigly	1.98 mmol/l	0.06	0.02	2.9	14
All methods	1.94 mmol/l	0.09	0.01	4.4	37



Round	Sample	x <sub>pt</sub>	Result	diff%	z-score
23/1	Sample S002	1.98	1.97	-0.16%	-0.05
23/1	Sample S001	1.05	1.07	2.09%	0.71







#### **Report info**

**Participants** 

51 participants from 15 countries.

**Report info** 

Your own result should be compared to others using the same method. Assigned values (x<sub>pt</sub>, target values) are means of the results where results deviating more than +/- 3\*standard deviation from the median are removed. The standard uncertainty (u) of


the assigned value is reported as standard error of the mean (SEM). Additionally, if the measurement uncertainty of the target value is large an automatic text is printed on the report: "The uncertainty of the assigned value is not negligible, and evaluations could be affected."
In case the client's result is the only one in the method group, no assigned value will be calculated, no target area shown, and no statistics calculated. In case there are only a few results in the client's own method group, the result can be compared to all method mean or to a group that is similar to the own method. Results reported with < or > -signs cannot be included in the statistics.


For information on report interpretation and performance evaluation, please see the "EQAS Interpretation guidelines" LabScala User instructions (top right corner? Help link).


28.03.2023 5/5



#### S-Lp(a) |Advia 1 and 2







Round	Sample	<sup>X</sup> pt	Result	diff%	z-score
23/1	Sample S003	581.11	589.00	1.36%	0.16







#### **Report info**

**Participants** 

51 participants from 15 countries.

**Report info** 

Your own result should be compared to others using the same method. Assigned values (x<sub>pt</sub>, target values) are means of the results where results deviating more than +/- 3\*standard deviation from the median are removed. The standard uncertainty (u) of

the assigned value is reported as standard error of the mean (SEM). Additionally, if the measurement uncertainty of the target value is large an automatic text is printed on the report: "The uncertainty of the assigned value is not negligible, and evaluations could be affected."
In case the client's result is the only one in the method group, no assigned value will be calculated, no target area shown, and no statistics calculated. In case there are only a few results in the client's own method group, the result can be compared to all method mean or to a group that is similar to the own method. Results reported with < or > -signs cannot be included in the statistics.

For information on report interpretation and performance evaluation, please see the "EQAS Interpretation guidelines" LabScala User instructions (top right corner? Help link).


28.03.2023 2/2



#### Sample S001 | S-Chol, mmol/l

Methodics	<sup>x</sup> pt	Median	sd	CV%	SEM	min	max	Outliers	n
NMR spectroscopy, Chol	5.05	5.10	0.19	3.7	0.11	4.84	5.20	-	3
Photometry, enzymatic, Abbott, Chol	4.83	4.86	0.07	1.4	0.02	4.73	4.91	-	8
Photometry, enzymatic, Atellica, Chol	4.83	4.80	0.06	1.2	0.03	4.80	4.90	-	3
Photometry, enzymatic, BC, Kol	5.20	5.20	<0.01	<0.1	<0.01	5.20	5.20	-	2
Photometry, enzymatic, Roche Chol	4.85	4.85	0.08	1.6	0.02	4.72	5.00	-	14
Photometry, enzymatic, Siemens Kol	4.79	4.79	0.13	2.7	0.09	4.70	4.88	-	2
Photometry, enzymatic, Thermo, Kol	5.03	5.10	0.11	2.2	0.05	4.85	5.10	-	5
All	4.90	4.86	0.14	2.8	0.02	4.70	5.20	-	37


#### Sample S001 | S-Chol, mmol/l| histogram summaries in LabScala



Photometry, enzymatic, Atellica, Chol


Target: ±5%)


xxx (x<sub>pt</sub>: 4.83 | Target area: 4.59-5.08 |




All method groups

# Lipids and lipoproteins, February, 1-2023










#### Sample S001 | S-Chol-HDL, mmol/l

Methodics	x <sub>pt</sub>	Median	sd	CV%	SEM	min	max	Outliers	n
Direct measurement, HDL-Chol, Abbott	1.56	1.57	0.03	2.2	0.01	1.51	1.61	-	8
Direct measurement, HDL-Chol, BC (AU-devices)	1.63	1.63	0.06	3.5	0.04	1.59	1.67	-	2
Direct measurement, HDL-chol, Roche-systems	1.67	1.66	0.04	2.4	0.01	1.62	1.73	-	14
Direct measurement, HDL-chol, Siemens	1.58	1.60	0.05	3.2	0.03	1.50	1.60	-	4
Direct measurement, HDL-chol, Siemens Advia	-	-	-	-	-	1.64	1.64	-	1
Direct measurement, HDL-chol, Thermo Scientific	1.72	1.71	0.03	1.7	0.01	1.68	1.76	-	5
NMR spectroscopy, Chol HDL	1.70	1.72	0.07	3.9	0.04	1.63	1.76	-	3
All	1.64	1.63	0.07	4.1	0.01	1.50	1.76	-	37


#### Sample S001 | S-Chol-HDL, mmol/l| histogram summaries in LabScala



Direct measurement, HDL-chol, Roche-


1.50-1.83 | Target: ±10%)


systems xxx ( $x_{pt}$ : 1.67 | Target area:




All method groups














#### Sample S001 | S-Chol-LDL, mmol/l

Methodics	x <sub>pt</sub>	Median	sd	CV%	SEM	min	max	Outliers	n
Direct measurement, LDL-chol, Roche-systems	2.73	2.73	0.06	2.4	0.02	2.59	2.84	-	15
Direct measurement, LDL-Chol, Abbott	3.05	3.03	0.07	2.2	0.02	2.96	3.18	-	8
Direct measurement, LDL-Chol, BC (AU-devices)	2.99	2.99	0.08	2.8	0.06	2.93	3.05	-	2
Direct measurement, LDL-chol, Siemens Advia & Atellica	3.00	3.00	0.42	14.1	0.30	2.70	3.30	-	2
Direct measurement, LDL-chol, Thermo Scientific	2.92	2.90	0.08	2.8	0.04	2.84	3.03	-	4
Direct measurement, LDL-kol, Siemens	2.99	2.99	0.02	0.7	0.02	2.97	3.00	-	2
LDL Friedewald	-	-	-	-	-	2.80	2.80	-	1
NMR spectroscopy, Chol-LDL	2.60	2.66	0.13	4.8	0.07	2.46	2.69	-	3
All	2.85	2.80	0.18	6.3	0.03	2.46	3.30	-	37

#### Sample S001 | S-Chol-LDL, mmol/l| histogram summaries in LabScala




2.8


mmol/l

2.69-3.29 | Target: ±10%)

Direct measurement, LDL-Chol, BC (AU-

devices) xxx ( $x_{pt}$ : 2.99 | Target area:






2.6


All method groups


27.03.2023

3.2

# Lipids and lipoproteins, February, 1-2023












#### Sample S001 | S-Trigly, mmol/l


Methodics	x <sub>pt</sub>	Median	sd	CV%	SEM	min	max	Outliers	n
Fotometria, entsymaattinen, Thermo, Trigl	1.04	1.03	0.03	2.4	0.01	1.02	1.08	-	5
NMR spectroscopy, Trigly	0.95	0.94	0.02	1.8	0.01	0.94	0.97	-	3
Photometry, enzymatic, Abbott, Trigly	0.97	0.97	0.04	4.1	0.01	0.93	1.03	-	8
Photometry, enzymatic, Atellica, Trigly	1.10	1.10	<0.01	<0.1	<0.01	1.10	1.10	-	3
Photometry, enzymatic, BC, Trigl	1.02	1.02	0.03	2.8	0.02	1.00	1.04	-	2
Photometry, enzymatic, Roche trigly	1.05	1.06	0.03	3.0	<0.01	1.00	1.11	-	14
Photometry, enzymatic, Siemens Trigly	1.09	1.09	0.06	5.2	0.04	1.05	1.13	-	2
All	1.03	1.03	0.05	5.2	<0.01	0.93	1.13	-	37

#### Sample S001 | S-Trigly, mmol/l| histogram summaries in LabScala










27.03.2023 7/29




All method groups

# Lipids and lipoproteins, February, 1-2023



Photometry, enzymatic, Siemens Trigly xxx (x<sub>pt</sub>: 1.09 | Target area: 0.93-1.25 |

Target: ±15%)








#### Sample S001 | S-LipoA1, g/l


Methodics	x <sub>pt</sub>	Median	sd	CV%	SEM	min	max	Outliers	n
Beckman Coulter (ApoA1)	-	-	-	-	-	1.61	1.61	-	1
Immunonefelometry, Apo-A1, Siemens	1.66	1.63	0.06	3.4	0.03	1.61	1.74	-	5
Immunoturbidimetry, Apo-A1, Abbott	1.69	1.70	0.04	2.5	0.02	1.65	1.73	-	3
Immunoturbidimetry, Apo-A1, Roche	1.62	1.60	0.06	3.6	0.03	1.55	1.70	-	5
Immunoturbidimetry, Apo-A1, Thermo Scientific	1.61	1.49	0.35	21.4	0.17	1.35	2.12	-	4
Immunoturbidometry Apo A1, Aidian (Orion Diagnostica)	-	-	-	-	-	1.56	1.56	-	1
Immunoturbidometry Apo A1 Siemens	1.44	1.46	0.07	4.5	0.03	1.33	1.50	-	5
NMR spectroscopy, ApoA1	1.65	1.66	0.06	3.4	0.03	1.59	1.70	-	3
All	1.58	1.61	0.11	7.1	0.02	1.33	1.74	1	27


#### Sample S001 | S-LipoA1, g/l| histogram summaries in LabScala







All method groups







Immunoturbidometry Apo A1, Aidian






## Sample S001 | S-LipoA2, g/l

Methodics	<sup>x</sup> pt	Median	sd	CV%	SEM	min	max	Outliers	n
Immunonephelometry Apo-A2, Siemens	0.25	0.25	0.01	5.7	0.01	0.24	0.26	-	2
All	0.25	0.25	0.01	5.7	0.01	0.24	0.26	-	2

## Sample S001 | S-LipoA2, g/l| histogram summaries in LabScala








#### Sample S001 | S-LipoB, g/l

Methodics	x <sub>pt</sub>	Median	sd	CV%	SEM	min	max	Outliers	n
Beckman Coulter (ApoB)	-	-	-	-	-	0.75	0.75	-	1
Immunonefelometry, Apo-B, Siemens	0.79	0.78	0.02	2.8	0.01	0.77	0.82	-	5
Immunoturbidimetry, Apo-B, Abbott	0.84	0.81	0.06	7.0	0.03	0.80	0.91	-	3
Immunoturbidimetry, Apo-B, Roche	0.86	0.86	0.03	3.8	0.01	0.80	0.91	-	7
Immunoturbidimetry, Apo-B, Thermo Scientific	0.81	0.81	0.02	2.9	0.01	0.79	0.83	-	4
Immunoturbidometry Apo B, Aidian (Orion Diagnostica)	-	-	-	-	-	0.76	0.76	-	1
Immunoturbidometry Apo B Siemens	0.78	0.80	0.04	5.3	0.02	0.71	0.81	-	5
NMR spectroscopy, ApoB	0.85	0.86	0.02	2.4	0.01	0.83	0.87	-	3
All	0.82	0.81	0.05	5.7	<0.01	0.71	0.91	-	29


#### Sample S001 | S-LipoB, g/l| histogram summaries in LabScala










# Lipids and lipoproteins, February, 1-2023













#### Sample S002 | S-Chol, mmol/l


Methodics	x <sub>pt</sub>	Median	sd	CV%	SEM	min	max	Outliers	n
NMR spectroscopy, Chol	3.22	3.32	0.21	6.5	0.12	2.98	3.36	-	3
Photometry, enzymatic, Abbott, Chol	2.68	2.70	0.06	2.2	0.02	2.56	2.74	-	8
Photometry, enzymatic, Atellica, Chol	2.63	2.60	0.06	2.2	0.03	2.60	2.70	-	3
Photometry, enzymatic, BC, Kol	2.80	2.80	<0.01	<0.1	<0.01	2.80	2.80	-	2
Photometry, enzymatic, Roche Chol	2.66	2.65	0.06	2.1	0.01	2.60	2.75	-	14
Photometry, enzymatic, Siemens Kol	2.65	2.65	0.06	2.4	0.05	2.60	2.69	-	2
Photometry, enzymatic, Thermo, Kol	2.81	2.80	0.06	2.1	0.03	2.74	2.90	-	5
All	2.70	2.70	0.09	3.4	0.02	2.56	2.98	2	37


#### Sample S002 | S-Chol, mmol/l| histogram summaries in LabScala





# Lipids and lipoproteins, February, 1-2023









#### Sample S002 | S-Chol-HDL, mmol/l


Methodics	x <sub>pt</sub>	Median	sd	CV%	SEM	min	max	Outliers	n
Direct measurement, HDL-Chol, Abbott	1.27	1.28	0.03	2.1	<0.01	1.22	1.30	-	8
Direct measurement, HDL-Chol, BC (AU-devices)	1.31	1.31	0.03	2.2	0.02	1.29	1.33	-	2
Direct measurement, HDL-chol, Roche-systems	1.27	1.28	0.03	2.3	<0.01	1.23	1.30	-	14
Direct measurement, HDL-chol, Siemens	1.18	1.20	0.05	4.3	0.03	1.10	1.20	-	4
Direct measurement, HDL-chol, Siemens Advia	-	-	-	-	-	1.12	1.12	-	1
Direct measurement, HDL-chol, Thermo Scientific	1.35	1.36	0.05	3.4	0.02	1.28	1.41	-	5
NMR spectroscopy, Chol HDL	1.21	1.22	0.06	4.6	0.03	1.15	1.26	-	3
All	1.26	1.28	0.06	5.0	0.01	1.10	1.41	-	37


#### Sample S002 | S-Chol-HDL, mmol/l| histogram summaries in LabScala

















#### Sample S002 | S-Chol-LDL, mmol/l

Methodics	x <sub>pt</sub>	Median	sd	CV%	SEM	min	max	Outliers	n
Direct measurement, LDL-chol, Roche-systems	0.68	0.68	0.02	2.9	<0.01	0.64	0.71	1	15
Direct measurement, LDL-Chol, Abbott	0.89	0.89	0.02	2.4	<0.01	0.86	0.93	-	8
Direct measurement, LDL-Chol, BC (AU-devices)	1.18	1.18	0.04	3.0	0.03	1.15	1.20	-	2
Direct measurement, LDL-chol, Siemens Advia & Atellica	0.80	0.80	0.28	35.4	0.20	0.60	1.00	-	2
Direct measurement, LDL-chol, Thermo Scientific	0.68	0.70	0.05	7.1	0.02	0.61	0.72	-	4
Direct measurement, LDL-kol, Siemens	0.97	0.97	0.05	5.1	0.04	0.93	1.00	-	2
LDL Friedewald	_	-	-	-	-	0.60	0.60	-	1
NMR spectroscopy, Chol-LDL	1.51	1.59	0.15	9.9	0.09	1.34	1.61	-	3
All	0.79	0.70	0.19	23.4	0.03	0.52	1.34	2	37


#### Sample S002 | S-Chol-LDL, mmol/l| histogram summaries in LabScala



■ Direct measurement, LDL-Chol, BC (AU-

1.06-1.29 | Target: ±10%)

devices) xxx ( $x_{pt}$ : 1.18 | Target area:





area: 0.72-0.88 | Target: ±10%)


All method groups


27.03.2023 18/29

# Lipids and lipoproteins, February, 1-2023












#### Sample S002 | S-Trigly, mmol/l

Methodics	x <sub>pt</sub>	Median	sd	CV%	SEM	min	max	Outliers	n
Fotometria, entsymaattinen, Thermo, Trigl	2.01	1.99	0.07	3.5	0.03	1.93	2.10	-	5
NMR spectroscopy, Trigly	1.80	1.80	0.04	1.9	0.02	1.77	1.84	-	3
Photometry, enzymatic, Abbott, Trigly	1.85	1.85	0.05	2.7	0.02	1.79	1.94	-	8
Photometry, enzymatic, Atellica, Trigly	2.00	2.00	<0.01	<0.1	<0.01	2.00	2.00	-	3
Photometry, enzymatic, BC, Trigl	1.96	1.96	0.03	1.4	0.02	1.94	1.98	-	2
Photometry, enzymatic, Roche trigly	1.98	1.97	0.06	2.9	0.02	1.90	2.07	-	14
Photometry, enzymatic, Siemens Trigly	2.00	2.00	0.06	2.8	0.04	1.96	2.04	-	2
All	1.94	1.95	0.09	4.4	0.01	1.77	2.10	-	37


#### Sample S002 | S-Trigly, mmol/l| histogram summaries in LabScala



mmol/l


Target: ±15%)


Photometry, enzymatic, Abbott, Trigly xxx (x<sub>pt</sub>: 1.85 | Target area: 1.57-2.13 |




All method groups













#### Sample S002 | S-LipoA1, g/l


Methodics	x <sub>pt</sub>	Median	sd	CV%	SEM	min	max	Outliers	n
Beckman Coulter (ApoA1)	-	-	-	-	-	1.60	1.60	-	1
Immunonefelometry, Apo-A1, Siemens	1.60	1.65	0.18	11.3	0.08	1.29	1.75	-	5
Immunoturbidimetry, Apo-A1, Abbott	1.69	1.70	0.03	1.8	0.02	1.66	1.72	-	3
Immunoturbidimetry, Apo-A1, Roche	1.62	1.61	0.07	4.1	0.03	1.53	1.70	-	5
Immunoturbidimetry, Apo-A1, Thermo Scientific	1.59	1.59	0.04	2.2	0.03	1.56	1.61	-	2
Immunoturbidometry Apo A1, Aidian (Orion Diagnostica)	-	-	-	-	-	1.67	1.67	-	1
Immunoturbidometry Apo A1 Siemens	1.44	1.46	0.06	3.9	0.03	1.35	1.49	-	5
NMR spectroscopy, ApoA1	1.52	1.54	0.06	3.7	0.03	1.46	1.57	-	3
All	1.58	1.60	0.12	7.4	0.02	1.29	1.75	-	25


#### Sample S002 | S-LipoA1, g/l| histogram summaries in LabScala













Target: ±15%)








## Sample S002 | S-LipoA2, g/l

Methodics	<sup>x</sup> pt	Median	sd	CV%	SEM	min	max	Outliers	n
Immunonephelometry Apo-A2, Siemens	0.32	0.32	0.01	4.4	0.01	0.31	0.33	-	2
All	0.32	0.32	0.01	4.4	0.01	0.31	0.33	-	2

## Sample S002 | S-LipoA2, g/l| histogram summaries in LabScala



0.55


0.55



#### Sample S002 | S-LipoB, g/l


Methodics	x <sub>pt</sub>	Median	sd	CV%	SEM	min	max	Outliers	n
Beckman Coulter (ApoB)	-	-	-	-	-	0.45	0.45	-	1
Immunonefelometry, Apo-B, Siemens	0.45	0.46	0.05	10.6	0.02	0.37	0.49	-	5
Immunoturbidimetry, Apo-B, Abbott	0.51	0.50	0.04	7.4	0.02	0.48	0.55	-	3
Immunoturbidimetry, Apo-B, Roche	0.47	0.47	0.04	8.2	0.01	0.40	0.52	-	7
Immunoturbidimetry, Apo-B, Thermo Scientific	0.57	0.57	0.02	2.7	<0.01	0.56	0.59	-	3
Immunoturbidometry Apo B, Aidian (Orion Diagnostica)	-	-	-	-	-	0.53	0.53	-	1
Immunoturbidometry Apo B Siemens	0.46	0.45	0.03	6.3	0.01	0.42	0.50	-	5
NMR spectroscopy, ApoB	0.54	0.55	0.03	4.9	0.02	0.51	0.56	-	3
All	0.49	0.48	0.05	10.9	0.01	0.37	0.59	-	28


## Sample S002 | S-LipoB, g/l| histogram summaries in LabScala




27.03.2023 25/29













#### Sample S003 | S-Lp(a), mg/l

Methodics	<sup>X</sup> pt	Median	sd	CV%	SEM	min	max	Outliers	n
Immunonephelometry, Lp(a), Siemens	371.00	372.50	10.68	2.9	5.34	359.00	380.00	-	4
Immunoturbidometry, Lp(a), Abbott	556.02	550.05	37.36	6.7	21.57	522.00	596.00	-	3
Immunoturbidometry Lp(a) Aidian (Orion Diagnostica)	-	-	-	-	-	569.80	569.80	-	1
Immunoturbidometry Lp(a) Optilite	-	-	-	-	-	488.37	488.37	-	1
Immunoturbidometry Lp(a) Roche	520.09	508.17	40.79	7.8	14.42	491.71	617.97	-	8
Immunoturbidometry Lp(a) Siemens	581.11	585.25	48.05	8.3	16.99	516.82	657.32	-	8
All	520.79	517.94	80.88	15.5	16.18	359.00	657.32	-	25

#### Sample S003 | S-Lp(a), mg/l| histogram summaries in LabScala






# Immunoturbidometry Lp(a) Aidian (Orion Diagnostica) 8 6 4 2 0 400 450 550 600 650


Diagnostica)


Immunoturbidometry Lp(a) Aidian (Orion



All method groups









#### **Report info**

**Participants** 

51 participants from 15 countries.

**Report info** 

Your own result should be compared to others using the same method. Assigned values (x<sub>pt</sub>, target values) are means of the results where results deviating more than +/- 3\*standard deviation from the median are removed. The standard uncertainty (u) of

the assigned value is reported as standard error of the mean (SEM). Additionally, if the measurement uncertainty of the target value is large an automatic text is printed on the report: "The uncertainty of the assigned value is not negligible, and evaluations could be affected."
In case the client's result is the only one in the method group, no assigned value will be calculated, no target area shown, and no statistics calculated. In case there are only a few results in the client's own method group, the result can be compared to all method mean or to a group that is similar to the own method. Results reported with < or > -signs cannot be included in the statistics.

For information on report interpretation and performance evaluation, please see the "EQAS Interpretation guidelines" LabScala User instructions (top right corner? Help link).

Copyright © Labquality Oy

27.03.2023 29/29

External Quality Assessment Scheme

#### Lipids and Lipoproteins Lp(a) Round 1, 2023

#### **Specimens**

Sample S001 (LQ735323011) and Sample S002 (LQ735323012) were fresh liquid unprocessed human sera (from single donors). Sample S003 (LQ735323013) was a lyophilized product obtained from human serum intended for Lp(a) measurements. Based on the results of this round, S001 and S002 (fresh samples) were homogeneous, stable and suitable for the external quality assessment scheme. Sample S003 based on the previous tests and the results of this round, was homogeneous, stable and suitable for the external quality assessment scheme.

The materials were sent without temperature control packaging.

#### Report info

It is important to read the Final report first, because it contains important information of the samples and results in each round.

#### **Comments - Expert**

The mean concentration for total cholesterol was 4.9 mmol/L in sample S001 and 2.7 mmol/L in sample S002. Repeatability between different method groups was good, coefficient of variation (CV) was 2.8% in sample S001 and 3.4% in sample S002. Repeatability for HDL-C was 4.1% in S001 (mean value 1.64 mmol/L) and 5.0% in S002 (mean value 1.26 mmol/L). The mean concentration for triglycerides was 1.0 mmol/L in S001 and 1.9 mmol/L in S002, and repeatability between different methods was 5.2% and 4.4%, respectively.

The mean concentration for LDL-C was 2.85 mmol/L in S001 and repeatability was 6.3%. The mean value for S002 was 0.79 mmol/L and concentrations varied between different method groups. The lowest concentrations were with Roche and Thermo Scientific methods (0.68 mmol/L) and the highest with NMR spectroscopy (1.51 mmol/L) and BC Au instruments (1.18 mmol/L). The largest variation between results was with Siemens Advia & Atellica group in both S001 and S002, 14.1% and 35.4%, respectively.

The mean concentration for apoA1 was 1.58 g/L in both S001 and S002 with different method groups. CVs were 7.1% and 7.4%, respectively. There were only two results for apoA2 with Siemens method group, the mean concentration was 0.25 g/L in S001 ja 0.32 g/L in S002. For apoB mean concentration was 0.82 g/L in S001 and 0.49 g/L in S002, CVs were 5.7% and 10.9%.

The mean value for Lp(a) in S003 with different method groups was 520.79 mg/L and CV was 15.5%. Because of the complex structure, it has been difficult to standardize Lp(a) assays.

#### **End of report**

#### 2023-04-13

#### **FINAL REPORT**

Product no. 2200, 2202

Subcontracting: Sample preparation

 Samples sent
 2023-02-21

 Round closed
 2023-03-16

 Final report
 2023-04-13

#### Request for correction

Typing errors in laboratory's result forms are on laboratory's responsibility. Labquality accepts responsibility only for result processing. Requests must be notified by writing within three weeks from the date of this letter.

#### Authorized by

EQA Coordinator Satu Eklund T. +358 45 773 107 87 satu.eklund@labquality.fi

#### **Expert**


Jaana Leiviskä, Adjunct professor, Clinical chemist, HUS Diagnostic Center, Vantaa, Finland

#### Labquality Oy

Kumpulantie 15 FI-00520 HELSINKI Finland

Tel. + 358 9 8566 8200 Fax + 358 9 8566 8280

info@labquality.fi www.labquality.com





Copyright © Labquality Oy

Labquality does not permit any reproduction for commercial purposes of any portion of the material subject to this copyright. Labquality prohibits any use of its name, or reference to Labquality EQA program, or material in this report in any advertising, brochures or other commercial publications. Labquality EQA data do not necessarily indicate the superiority of instruments, reagents, testing equipments or materials used by participating laboratories. Use of Labquality EQA data to suggest superiority or inferiority of equipments or materials may be deceptive and misleading. Proficiency test results are handled confidentially. Labquality will not issue any statements to third parties of the performance of laboratories in external quality assessment schemes unless otherwise agreed.